GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Cash Flow from Financing

Inoviq (ASX:IIQ) Cash Flow from Financing : A$-0.28 Mil (TTM As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Inoviq Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Inoviq paid A$0.00 Mil more to buy back shares than it received from issuing new shares. It received A$0.00 Mil from issuing more debt. It paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received A$0.00 Mil from paying cash dividends to shareholders. It received A$0.00 Mil on other financial activities. In all, Inoviq spent A$0.00 Mil on financial activities for the six months ended in Dec. 2023.


Inoviq Cash Flow from Financing Historical Data

The historical data trend for Inoviq's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inoviq Cash Flow from Financing Chart

Inoviq Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.68 2.31 -0.05 16.87 -0.27

Inoviq Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.08 -0.20 -0.14 -0.12 -0.16

Inoviq Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Inoviq's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:

Inoviq's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inoviq  (ASX:IIQ) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Inoviq's issuance of stock for the six months ended in Dec. 2023 was A$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Inoviq's repurchase of stock for the six months ended in Dec. 2023 was A$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Inoviq's net issuance of debt for the six months ended in Dec. 2023 was A$0.00 Mil. Inoviq received A$0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Inoviq's net issuance of preferred for the six months ended in Dec. 2023 was A$0.00 Mil. Inoviq paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Inoviq's cash flow for dividends for the six months ended in Dec. 2023 was A$0.00 Mil. Inoviq received A$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Inoviq's other financing for the six months ended in Dec. 2023 was A$0.00 Mil. Inoviq received A$0.00 Mil on other financial activities.


Inoviq Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Inoviq's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Inoviq (ASX:IIQ) Business Description

Traded in Other Exchanges
N/A
Address
23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Inoviq (ASX:IIQ) Headlines

No Headlines